{"url_path":"/sec/ctxr/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1506251/0001213900-26-057842-index.html","accession_number":"0001213900-26-057842","cik":"0001506251","ticker":"CTXR","issuer_name":"Citius Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1506251/0001213900-26-057842-index.html","primary_entity_key":"0001506251","primary_entity_name":"Citius Pharmaceuticals, Inc."},"word_count":1582,"has_tables":true,"body_markdown":"** **\n\n**Item 6. Exhibits.**\n\n \n\n4.1\n \n[Form of Warrant issued on April 24, 2026 (incorporated by reference to Exhibit 4.1 to the Form 8-K filed on April 24, 2026).](http://www.sec.gov/Archives/edgar/data/1506251/000121390026047599/ea028762001ex4-1.htm)\n\n \n \n \n\n4.2\n \n[Form of Pre-Funded Warrant issued on April 24, 2026 (incorporated by reference to Exhibit 4.2 to the Form 8-K filed on April 24, 2026).](http://www.sec.gov/Archives/edgar/data/1506251/000121390026047599/ea028762001ex4-2.htm)\n\n \n \n \n\n4.3\n \n[Form of Placement Agent Warrant issued on April 24, 2026 (incorporated by reference to Exhibit 4.3 to the Form 8-K filed on April 24, 2026).](http://www.sec.gov/Archives/edgar/data/1506251/000121390026047599/ea028762001ex4-3.htm)\n\n \n \n \n\n10.1\n \n[Form of Securities Purchase Agreement, dated as of April 24, 2026, by and among Citius Pharmaceuticals, Inc. and the investor signatory thereto (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on April 24, 2026).](http://www.sec.gov/Archives/edgar/data/1506251/000121390026047599/ea028762001ex10-1.htm)\n\n \n \n \n\n10.2\n \n[Third Amendment to Promissory Note, dated May 4, 2026, by and between Citius Oncology, Inc. and Citius Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on May 8, 2026).](https://www.sec.gov/Archives/edgar/data/1506251/000121390026053916/ea028973101ex10-1.htm)\n\n \n \n \n\n31.1\n \n[Certification of the Principal Executive Officer pursuant to Exchange Act Rule 13a-14(a).*](ea029055201ex31-1.htm)\n\n \n \n \n\n31.2\n \n[Certification of the Principal Financial Officer pursuant to Exchange Act Rule 13a-14(a).*](ea029055201ex31-2.htm)\n\n \n \n \n\n32.1\n \n[Certification of the Principal Executive and Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.*](ea029055201ex32-1.htm)\n\n \n \n \n\nEX-101.INS\n \nInline XBRL Instance Document*\n\n \n \n \n\nEX-101.SCH\n \nInline XBRL Taxonomy Extension Schema Document*\n\n \n \n \n\nEX-101.CAL\n \nInline XBRL Taxonomy Extension Calculation Linkbase Document*\n\n \n \n \n\nEX-101.DEF\n \nInline XBRL Taxonomy Extension Definition Linkbase Document*\n\n \n \n \n\nEX-101.LAB\n \nInline XBRL Taxonomy Extension Label Linkbase Document*\n\n \n \n \n\nEX-101.PRE\n \nInline XBRL Taxonomy Extension Presentation Linkbase Document*\n\n \n \n \n\nEX-104\n \nCover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)*\n\n \n\n*\nFiled herewith.\n\n** **\n\n37\n\n \n\n** **\n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.\n\n \n\n \n**CITIUS PHARMACEUTICALS, INC.**\n\n \n \n \n\nDate: May 15, 2026\nBy: \n/s/ *Leonard Mazur*\n\n \n \nLeonard Mazur\n\n \n \nChief Executive Officer\n\n(Principal Executive Officer)\n\n \n \n \n\nDate: May 15, 2026\nBy: \n/s/ *Jaime Bartushak*\n\n \n \nJaime Bartushak\n\n \n \nChief Financial Officer\n\n(Principal Financial and Accounting Officer)\n\n \n\n \n\n38\n\n \n\n0001506251\nfalse\nQ2\n--09-30\n\n0001506251\n\n2025-10-01\n2026-03-31\n\n0001506251\n\n2026-05-14\n\n0001506251\n\n2026-03-31\n\n0001506251\n\n2025-09-30\n\n0001506251\n\n2026-01-01\n2026-03-31\n\n0001506251\n\n2025-01-01\n2025-03-31\n\n0001506251\n\n2024-10-01\n2025-03-31\n\n0001506251\n\nus-gaap:PreferredStockMember\n\n2025-09-30\n\n0001506251\n\nus-gaap:CommonStockMember\n\n2025-09-30\n\n0001506251\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-09-30\n\n0001506251\n\nus-gaap:RetainedEarningsMember\n\n2025-09-30\n\n0001506251\n\nus-gaap:ParentMember\n\n2025-09-30\n\n0001506251\n\nus-gaap:NoncontrollingInterestMember\n\n2025-09-30\n\n0001506251\n\nus-gaap:PreferredStockMember\n\n2025-10-01\n2025-12-31\n\n0001506251\n\nus-gaap:CommonStockMember\n\n2025-10-01\n2025-12-31\n\n0001506251\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-10-01\n2025-12-31\n\n0001506251\n\nus-gaap:RetainedEarningsMember\n\n2025-10-01\n2025-12-31\n\n0001506251\n\nus-gaap:ParentMember\n\n2025-10-01\n2025-12-31\n\n0001506251\n\nus-gaap:NoncontrollingInterestMember\n\n2025-10-01\n2025-12-31\n\n0001506251\n\n2025-10-01\n2025-12-31\n\n0001506251\n\nus-gaap:PreferredStockMember\n\n2025-12-31\n\n0001506251\n\nus-gaap:CommonStockMember\n\n2025-12-31\n\n0001506251\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-12-31\n\n0001506251\n\nus-gaap:RetainedEarningsMember\n\n2025-12-31\n\n0001506251\n\nus-gaap:ParentMember\n\n2025-12-31\n\n0001506251\n\nus-gaap:NoncontrollingInterestMember\n\n2025-12-31\n\n0001506251\n\n2025-12-31\n\n0001506251\n\nus-gaap:PreferredStockMember\n\n2026-01-01\n2026-03-31\n\n0001506251\n\nus-gaap:CommonStockMember\n\n2026-01-01\n2026-03-31\n\n0001506251\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-01-01\n2026-03-31\n\n0001506251\n\nus-gaap:RetainedEarningsMember\n\n2026-01-01\n2026-03-31\n\n0001506251\n\nus-gaap:ParentMember\n\n2026-01-01\n2026-03-31\n\n0001506251\n\nus-gaap:NoncontrollingInterestMember\n\n2026-01-01\n2026-03-31\n\n0001506251\n\nus-gaap:PreferredStockMember\n\n2026-03-31\n\n0001506251\n\nus-gaap:CommonStockMember\n\n2026-03-31\n\n0001506251\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-03-31\n\n0001506251\n\nus-gaap:RetainedEarningsMember\n\n2026-03-31\n\n0001506251\n\nus-gaap:ParentMember\n\n2026-03-31\n\n0001506251\n\nus-gaap:NoncontrollingInterestMember\n\n2026-03-31\n\n0001506251\n\nus-gaap:PreferredStockMember\n\n2024-09-30\n\n0001506251\n\nus-gaap:CommonStockMember\n\n2024-09-30\n\n0001506251\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-09-30\n\n0001506251\n\nus-gaap:RetainedEarningsMember\n\n2024-09-30\n\n0001506251\n\nus-gaap:ParentMember\n\n2024-09-30\n\n0001506251\n\nus-gaap:NoncontrollingInterestMember\n\n2024-09-30\n\n0001506251\n\n2024-09-30\n\n0001506251\n\nus-gaap:PreferredStockMember\n\n2024-10-01\n2024-12-31\n\n0001506251\n\nus-gaap:CommonStockMember\n\n2024-10-01\n2024-12-31\n\n0001506251\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-10-01\n2024-12-31\n\n0001506251\n\nus-gaap:RetainedEarningsMember\n\n2024-10-01\n2024-12-31\n\n0001506251\n\nus-gaap:ParentMember\n\n2024-10-01\n2024-12-31\n\n0001506251\n\nus-gaap:NoncontrollingInterestMember\n\n2024-10-01\n2024-12-31\n\n0001506251\n\n2024-10-01\n2024-12-31\n\n0001506251\n\nus-gaap:PreferredStockMember\n\n2024-12-31\n\n0001506251\n\nus-gaap:CommonStockMember\n\n2024-12-31\n\n0001506251\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-12-31\n\n0001506251\n\nus-gaap:RetainedEarningsMember\n\n2024-12-31\n\n0001506251\n\nus-gaap:ParentMember\n\n2024-12-31\n\n0001506251\n\nus-gaap:NoncontrollingInterestMember\n\n2024-12-31\n\n0001506251\n\n2024-12-31\n\n0001506251\n\nus-gaap:PreferredStockMember\n\n2025-01-01\n2025-03-31\n\n0001506251\n\nus-gaap:CommonStockMember\n\n2025-01-01\n2025-03-31\n\n0001506251\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-01-01\n2025-03-31\n\n0001506251\n\nus-gaap:RetainedEarningsMember\n\n2025-01-01\n2025-03-31\n\n0001506251\n\nus-gaap:ParentMember\n\n2025-01-01\n2025-03-31\n\n0001506251\n\nus-gaap:NoncontrollingInterestMember\n\n2025-01-01\n2025-03-31\n\n0001506251\n\nus-gaap:CommonStockMember\n\n2025-03-31\n\n0001506251\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-03-31\n\n0001506251\n\nus-gaap:RetainedEarningsMember\n\n2025-03-31\n\n0001506251\n\nus-gaap:ParentMember\n\n2025-03-31\n\n0001506251\n\nus-gaap:NoncontrollingInterestMember\n\n2025-03-31\n\n0001506251\n\n2025-03-31\n\n0001506251\n\nctxr:LeonardMeronBiosciencesIncMember\n\n2016-03-30\n\n0001506251\n\nctxr:DelwareCorporationMember\n\n2020-09-11\n\n0001506251\n\nctxr:CitiusOncologyIncMember\n\n2024-08-12\n\n0001506251\n\nctxr:CitiusOncologyIncMember\n\n2025-12-31\n\n0001506251\n\nctxr:CitiusOncologyIncMember\nctxr:WhollyOwnedSubsidiaryMember\n\n2026-03-31\n\n0001506251\n\nus-gaap:CommonStockMember\nus-gaap:SubsequentEventMember\n\n2026-04-24\n2026-04-24\n\n0001506251\n\nus-gaap:SubsequentEventMember\n\n2026-04-24\n\n0001506251\n\nus-gaap:SubsequentEventMember\n\n2026-04-24\n2026-04-24\n\n0001506251\n\nus-gaap:SubsequentEventMember\n\n2026-05-05\n2026-05-05\n\n0001506251\n\nus-gaap:SubsequentEventMember\n\n2026-05-05\n\n0001506251\n\nsrt:MinimumMember\nus-gaap:SubsequentEventMember\n\n2026-05-05\n\n0001506251\n\nsrt:MaximumMember\nus-gaap:SubsequentEventMember\n\n2026-05-05\n\n0001506251\n\nctxr:CitiusOncologyMember\n\n2026-03-31\n\n0001506251\n\nctxr:SalesAllowancesMember\n\n2026-03-31\n\n0001506251\n\nctxr:GrossProductRevenueMember\n\n2026-01-01\n2026-03-31\n\n0001506251\n\nctxr:GrossProductRevenueMember\n\n2025-10-01\n2026-03-31\n\n0001506251\n\nctxr:GrosstonetAdjustmentsMember\n\n2026-01-01\n2026-03-31\n\n0001506251\n\nctxr:GrosstonetAdjustmentsMember\n\n2025-10-01\n2026-03-31\n\n0001506251\n\nctxr:LYMPHIRMember\n\n2025-10-01\n2026-03-31\n\n0001506251\n\nctxr:LMBAndMinoLokMember\n\n2025-10-01\n2026-03-31\n\n0001506251\n\nctxr:LYMPHIRMember\n\n2026-03-31\n\n0001506251\n\n2024-10-01\n2025-09-30\n\n0001506251\n\n2023-10-01\n2024-09-30\n\n0001506251\n\nsrt:MinimumMember\nctxr:PatentAndTechnologyLicenseAgreementMinoLokMember\n\n2025-10-01\n2026-03-31\n\n0001506251\n\nsrt:MaximumMember\nctxr:PatentAndTechnologyLicenseAgreementMinoLokMember\n\n2025-10-01\n2026-03-31\n\n0001506251\n\nsrt:MinimumMember\n\n2025-10-01\n2026-03-31\n\n0001506251\n\nsrt:MaximumMember\n\n2025-10-01\n2026-03-31\n\n0001506251\n\nctxr:PatentAndTechnologyLicenseAgreementMinoLokMember\n\n2025-10-01\n2026-03-31\n\n0001506251\n\nctxr:NoveCiteMember\nctxr:LicenseAgreementEternaMember\n\n2021-09-30\n2021-09-30\n\n0001506251\n\nctxr:NoveCiteMember\nctxr:LicenseAgreementEternaMember\n\n2021-09-30\n\n0001506251\n\nctxr:LicenseAgreementMember\nctxr:LicenseAgreementEternaMember\n\n2021-09-30\n\n0001506251\n\nctxr:LicenseAgreementEternaMember\n\n2025-10-01\n2026-03-31\n\n0001506251\n\nsrt:MinimumMember\nctxr:LicenseAgreementEternaMember\n\n2025-10-01\n2026-03-31\n\n0001506251\n\nsrt:MaximumMember\nctxr:LicenseAgreementEternaMember\n\n2025-10-01\n2026-03-31\n\n0001506251\n\nctxr:LicenseAgreementEternaMember\n\n2026-03-31\n\n0001506251\n\nctxr:DrReddysLaboratoriesLtdMember\nctxr:LicenseAgreementWithEisaiMember\n\n2025-10-01\n2026-03-31\n\n0001506251\n\nctxr:DrReddysLaboratoriesLtdMember\nctxr:CTCLMember\n\n2026-03-31\n\n0001506251\n\nsrt:MaximumMember\nctxr:LicenseAgreementWithEisaiMember\n\n2026-03-31\n\n0001506251\n\nus-gaap:RoyaltyMember\nsrt:MinimumMember\nctxr:LicenseAgreementWithEisaiMember\n\n2025-10-01\n2026-03-31\n\n0001506251\n\nus-gaap:RoyaltyMember\nsrt:MaximumMember\nctxr:LicenseAgreementWithEisaiMember\n\n2025-10-01\n2026-03-31\n\n0001506251\n\nus-gaap:RoyaltyMember\nsrt:MinimumMember\nctxr:LicenseAgreementWithEisaiMember\n\n2025-10-01\n2025-12-31\n\n0001506251\n\nus-gaap:RoyaltyMember\nsrt:MaximumMember\nctxr:LicenseAgreementWithEisaiMember\n\n2025-10-01\n2025-12-31\n\n0001506251\n\nctxr:LicenseAgreementWithEisaiMember\n\n2025-10-01\n2025-12-31\n\n0001506251\n\nctxr:LYMPHIRMember\n\n2025-10-01\n2026-03-31\n\n0001506251\n\nctxr:DrReddysLaboratoriesLtdMember\n\n2026-03-31\n\n0001506251\n\nctxr:EisaiMember\n\n2025-10-01\n2026-03-31\n\n0001506251\n\nctxr:CitiusOncologyMember\n\n2026-03-31\n\n0001506251\n\nctxr:LicenseAgreementWithEisaiMember\n\n2025-07-15\n\n0001506251\n\n2025-07-15\n2025-07-15\n\n0001506251\n\n2025-07-15\n\n0001506251\n\nctxr:LicenseAgreementWithEisaiMember\n\n2026-03-31\n\n0001506251\n\n2025-06-02\n\n0001506251\n\nctxr:NotePayableMember\n\n2025-12-02\n2025-12-02\n\n0001506251\n\nus-gaap:CommonStockMember\n\n2025-12-02\n\n0001506251\n\nus-gaap:WarrantMember\n\n2025-10-01\n2026-03-31\n\n0001506251\n\nsrt:MaximumMember\n\n2026-03-31\n\n0001506251\n\nsrt:MinimumMember\n\n2026-03-31\n\n0001506251\n\nus-gaap:SeriesAPreferredStockMember\n\n2025-04-17\n2025-04-17\n\n0001506251\n\nus-gaap:SeriesAPreferredStockMember\n\n2025-04-17\n\n0001506251\n\nctxr:MrMazurMember\nus-gaap:SeriesAPreferredStockMember\n\n2025-04-17\n\n0001506251\n\nsrt:MinimumMember\nus-gaap:SeriesAPreferredStockMember\n\n2025-04-17\n\n0001506251\n\nsrt:MaximumMember\nus-gaap:SeriesAPreferredStockMember\n\n2025-04-17\n\n0001506251\n\nus-gaap:SeriesAPreferredStockMember\n\n2025-06-09\n\n0001506251\n\nus-gaap:CommonStockMember\n\n2025-07-01\n2025-07-01\n\n0001506251\n\nus-gaap:InvestorMember\nus-gaap:CommonStockMember\n\n2025-07-01\n2025-07-01\n\n0001506251\n\nus-gaap:CommonStockMember\n\n2025-10-02\n2025-10-02\n\n0001506251\n\nus-gaap:InvestorMember\nus-gaap:CommonStockMember\n\n2025-10-02\n2025-10-02\n\n0001506251\n\nctxr:CommonStockOfferingsMember\n\n2024-11-15\n2024-11-15\n\n0001506251\n\nctxr:November2024OfferingAgentMember\n\n2024-11-15\n\n0001506251\n\nus-gaap:WarrantMember\n\n2024-11-15\n\n0001506251\n\nus-gaap:InvestorMember\nctxr:CommonStockOfferingsMember\n\n2024-11-15\n\n0001506251\n\n2024-11-15\n2024-11-15\n\n0001506251\n\nctxr:CommonStockOfferingsMember\n\n2024-11-15\n\n0001506251\n\nus-gaap:WarrantMember\nctxr:CommonStockOfferingsMember\n\n2024-11-15\n\n0001506251\n\nus-gaap:WarrantMember\nus-gaap:CommonStockMember\n\n2024-11-15\n\n0001506251\n\nctxr:CommonStockOfferingsMember\n\n2025-01-07\n2025-01-07\n\n0001506251\n\nctxr:CommonStockOfferingsMember\n\n2025-01-07\n\n0001506251\n\nctxr:January2025OfferingMember\n\n2025-01-07\n\n0001506251\n\n2025-01-07\n2025-01-07\n\n0001506251\n\nus-gaap:WarrantMember\n\n2025-01-07\n\n0001506251\n\nus-gaap:WarrantMember\nctxr:CommonStockIssuedForServicesMember\n\n2025-01-07\n\n0001506251\n\nus-gaap:CommonStockMember\n\n2025-04-01\n2025-04-01\n\n0001506251\n\nus-gaap:CommonStockMember\n\n2025-04-01\n\n0001506251\n\nctxr:PrefundedWarrantsMember\nctxr:CommonStockOfferingsMember\n\n2025-04-01\n\n0001506251\n\nctxr:PrefundedWarrantsMember\n\n2025-04-01\n\n0001506251\n\n2025-04-01\n2025-04-01\n\n0001506251\n\nctxr:PrefundedWarrantsMember\nus-gaap:CommonStockMember\n\n2025-04-01\n\n0001506251\n\nctxr:PrefundedWarrantsMember\n\n2025-04-01\n2025-06-30\n\n0001506251\n\n2025-04-01\n\n0001506251\n\nctxr:CommonStockOfferingsMember\n\n2025-04-01\n\n0001506251\n\nus-gaap:CommonStockMember\n\n2024-04-01\n2024-04-01\n\n0001506251\n\nus-gaap:CommonStockMember\n\n2025-06-11\n2025-06-11\n\n0001506251\n\nctxr:PrefundedWarrantsMember\n\n2025-06-11\n\n0001506251\n\nus-gaap:WarrantMember\n\n2025-06-11\n\n0001506251\n\nus-gaap:CommonStockMember\n\n2025-06-11\n\n0001506251\n\nctxr:PrefundedWarrantsMember\nus-gaap:CommonStockMember\n\n2025-06-11\n\n0001506251\n\n2025-06-11\n2025-06-11\n\n0001506251\n\nctxr:PrefundedWarrantsMember\nus-gaap:CommonStockMember\n\n2024-10-01\n2025-09-30\n\n0001506251\n\nctxr:PrefundedWarrantsMember\n\n2025-06-11\n2025-06-11\n\n0001506251\n\nctxr:PlacementAgentWarrantsMember\n\n2025-06-11\n2025-06-11\n\n0001506251\n\nctxr:PlacementAgentWarrantsMember\nus-gaap:CommonStockMember\n\n2025-06-11\n\n0001506251\n\nctxr:CommonStockOfferingsMember\n\n2025-06-11\n\n0001506251\n\n2025-06-11\n\n0001506251\n\nctxr:CommonStockOfferingsMember\n\n2025-07-17\n2025-07-17\n\n0001506251\n\nctxr:CommonStockOfferingsMember\n\n2025-07-17\n\n0001506251\n\nus-gaap:CommonStockMember\n\n2025-07-17\n\n0001506251\n\nus-gaap:WarrantMember\nus-gaap:CommonStockMember\n\n2025-07-17\n\n0001506251\n\nus-gaap:WarrantMember\n\n2025-07-17\n\n0001506251\n\n2025-07-17\n\n0001506251\n\n2025-07-17\n2025-07-17\n\n0001506251\n\nus-gaap:WarrantMember\n\n2025-12-08\n\n0001506251\n\nctxr:PlacementAgentWarrantsMember\n\n2025-07-17\n\n0001506251\n\nctxr:July2025CitiusOncologyOfferingMember\n\n2025-07-17\n\n0001506251\n\n2025-09-10\n2025-09-10\n\n0001506251\n\n2025-09-10\n\n0001506251\n\nus-gaap:CommonStockMember\n\n2025-09-10\n\n0001506251\n\nus-gaap:WarrantMember\nus-gaap:CommonStockMember\n\n2025-09-10\n\n0001506251\n\nctxr:September2025CitiusOncologyOfferingMember\n\n2025-09-10\n\n0001506251\n\nsrt:BoardOfDirectorsChairmanMember\nus-gaap:WarrantMember\nus-gaap:CommonStockMember\n\n2025-09-10\n\n0001506251\n\nus-gaap:WarrantMember\n\n2025-09-10\n\n0001506251\n\nctxr:PlacementAgentWarrantsMember\n\n2025-09-10\n\n0001506251\n\nctxr:PlacementAgentWarrantsMember\n\n2025-09-10\n2025-09-10\n\n0001506251\n\nctxr:CitiusOncologyMember\n\n2025-09-10\n\n0001506251\n\nctxr:October2025OfferingMember\nus-gaap:CommonStockMember\n\n2025-10-21\n\n0001506251\n\nctxr:PrefundedWarrantsMember\nus-gaap:CommonStockMember\n\n2025-10-21\n2025-10-21\n\n0001506251\n\nctxr:PrefundedWarrantsMember\nus-gaap:CommonStockMember\n\n2025-10-21\n\n0001506251\n\nus-gaap:CommonStockMember\n\n2025-10-21\n\n0001506251\n\nctxr:PrefundedWarrantsMember\n\n2025-10-21\n\n0001506251\n\nus-gaap:WarrantMember\nus-gaap:CommonStockMember\n\n2025-10-21\n\n0001506251\n\nus-gaap:WarrantMember\nctxr:CommonStockOfferingsMember\n\n2025-10-21\n2025-10-21\n\n0001506251\n\nctxr:PrefundedWarrantsMember\nus-gaap:CommonStockMember\n\n2025-10-01\n2026-03-31\n\n0001506251\n\nctxr:October2025OfferingMember\n\n2025-10-21\n\n0001506251\n\nctxr:CitiusPharmaMember\n\n2025-10-21\n\n0001506251\n\nctxr:October2025OfferingMember\n\n2025-10-21\n2025-10-21\n\n0001506251\n\nctxr:October2025OfferingMember\nus-gaap:InvestorMember\nus-gaap:CommonStockMember\n\n2025-10-21\n2025-10-21\n\n0001506251\n\nctxr:PrefundedWarrantsMember\nctxr:October2025OfferingMember\nus-gaap:CommonStockMember\n\n2025-10-21\n\n0001506251\n\nctxr:October2025OfferingMember\nctxr:CommonStockOfferingsMember\n\n2025-10-21\n\n0001506251\n\nsrt:BoardOfDirectorsChairmanMember\nctxr:PrefundedWarrantsMember\nus-gaap:CommonStockMember\n\n2025-12-10\n2025-12-10\n\n0001506251\n\nctxr:PrefundedWarrantsMember\nus-gaap:CommonStockMember\n\n2025-12-10\n\n0001506251\n\nus-gaap:CommonStockMember\n\n2025-12-10\n\n0001506251\n\nctxr:PrefundedWarrantsMember\nus-gaap:CommonStockMember\n\n2025-12-10\n2025-12-10\n\n0001506251\n\nctxr:December2025CitiusOncologyOfferingMember\nus-gaap:CommonStockMember\n\n2025-12-10\n\n0001506251\n\nctxr:CommonStockOfferingsMember\n\n2025-12-10\n2025-12-10\n\n0001506251\n\nctxr:December2025CitiusOncologyOfferingMember\n\n2025-12-10\n2025-12-10\n\n0001506251\n\nctxr:December2025CitiusOncologyOfferingMember\n\n2025-12-10\n\n0001506251\n\nus-gaap:WarrantMember\n\n2025-12-10\n\n0001506251\n\n2025-12-10\n\n0001506251\n\n2025-12-10\n2025-12-10\n\n0001506251\n\nsrt:BoardOfDirectorsChairmanMember\nctxr:December2025CitiusOncologyOfferingMember\n\n2025-12-10\n2025-12-10\n\n0001506251\n\nsrt:BoardOfDirectorsChairmanMember\nctxr:December2025CitiusOncologyOfferingMember\n\n2025-12-10\n\n0001506251\n\nsrt:BoardOfDirectorsChairmanMember\n\n2025-12-10\n2025-12-10\n\n0001506251\n\nsrt:BoardOfDirectorsChairmanMember\n\n2025-12-10\n\n0001506251\n\nsrt:BoardOfDirectorsChairmanMember\nctxr:CitiusPharmaceuticalsWarrantsMember\nus-gaap:StockOptionMember\nctxr:CitiusOncologyPlanMember\nus-gaap:CommonStockMember\n\n2025-12-10\n\n0001506251\n\nctxr:CitiusPharmaceuticalsMember\n\n2025-12-10\n\n0001506251\n\nctxr:AtTheMarketOfferingAgreementMember\n\n2025-01-01\n2025-03-31\n\n0001506251\n\nctxr:AtTheMarketOfferingAgreementMember\n\n2025-04-01\n2025-06-30\n\n0001506251\n\n2025-04-01\n2025-06-30\n\n0001506251\n\n2025-07-01\n2025-09-30\n\n0001506251\n\nctxr:PrefundedWarrantsMember\nus-gaap:CommonStockMember\n\n2025-10-01\n2025-12-31\n\n0001506251\n\nctxr:TwoThousandFourteenStockPlanMember\n\n2026-03-31\n\n0001506251\n\nctxr:TwoThousandEighteenStockPlanMember\n\n2026-03-31\n\n0001506251\n\nctxr:TwoThousandTwentyMember\n\n2026-03-31\n\n0001506251\n\nctxr:TwoThousandTwentyOneStockPlanMember\n\n2026-03-31\n\n0001506251\n\nctxr:TwoThousandTwentyThreeStockPlanMember\n\n2026-03-31\n\n0001506251\n\nus-gaap:CommonStockMember\n\n2024-10-01\n2025-03-31\n\n0001506251\n\nus-gaap:StockOptionMember\n\n2026-03-31\n\n0001506251\n\nus-gaap:StockOptionMember\nctxr:CitiusOncologyPlanMember\n\n2025-10-01\n2026-03-31\n\n0001506251\n\nctxr:NoveCitePlanMember\n\n2026-03-31\n\n0001506251\n\nus-gaap:StockOptionMember\nus-gaap:CommonStockMember\n\n2025-10-01\n2026-03-31\n\n0001506251\n\nctxr:TwoThousandEighteenOmnibusStockIncentivePlanMember\n\n2026-03-31\n\n0001506251\n\nctxr:CitiusOncologyPlanMember\n\n2023-04-29\n\n0001506251\n\nctxr:PrefundedWarrantsMember\nctxr:CitiusOncologyMember\nus-gaap:CommonStockMember\n\n2026-03-31\n\n0001506251\n\nctxr:CitiusOncologyStockPlansMember\nus-gaap:CommonStockMember\n\n2026-03-31\n\n0001506251\n\nctxr:CitiusOncologyPlanMember\n\n2025-10-01\n2025-12-31\n\n0001506251\n\nctxr:CitiusOncologyStockPlansMember\n\n2026-03-31\n\n0001506251\n\nctxr:PrefundedWarrantsMember\nus-gaap:StockOptionMember\nctxr:CitiusOncologyPlanMember\nus-gaap:CommonStockMember\n\n2025-10-01\n2026-03-31\n\n0001506251\n\nctxr:CitiusOncologyRestrictedStockAwardsMember\n\n2025-09-19\n\n0001506251\n\n2026-03-24\n\n0001506251\n\nctxr:CitiusOncologyPlanMember\n\n2026-03-31\n\n0001506251\n\nctxr:CitiusOncologyPlanMember\n\n2025-10-01\n2026-03-31\n\n0001506251\n\nctxr:PrefundedWarrantsMember\nus-gaap:CommonStockMember\n\n2026-01-01\n2026-03-31\n\n0001506251\n\nctxr:PrefundedWarrantsMember\nctxr:CitiusPharmaMember\nus-gaap:CommonStockMember\n\n2026-01-01\n2026-03-31\n\n0001506251\n\nctxr:PrefundedWarrantsMember\nctxr:CitiusOncologyMember\nus-gaap:CommonStockMember\n\n2026-01-01\n2026-03-31\n\n0001506251\n\nctxr:PrefundedWarrantsMember\nctxr:CitiusOncologyRestrictedStockMember\nus-gaap:CommonStockMember\n\n2026-01-01\n2026-03-31\n\n0001506251\n\nctxr:PrefundedWarrantsMember\nus-gaap:CommonStockMember\n\n2025-01-01\n2025-03-31\n\n0001506251\n\nctxr:PrefundedWarrantsMember\nctxr:CitiusPharmaMember\nus-gaap:CommonStockMember\n\n2025-01-01\n2025-03-31\n\n0001506251\n\nctxr:PrefundedWarrantsMember\nctxr:CitiusOncologyMember\nus-gaap:CommonStockMember\n\n2025-01-01\n2025-03-31\n\n0001506251\n\nctxr:PrefundedWarrantsMember\nctxr:CitiusPharmaMember\nus-gaap:CommonStockMember\n\n2025-10-01\n2026-03-31\n\n0001506251\n\nctxr:PrefundedWarrantsMember\nctxr:CitiusOncologyMember\nus-gaap:CommonStockMember\n\n2025-10-01\n2026-03-31\n\n0001506251\n\nctxr:PrefundedWarrantsMember\nctxr:CitiusOncologyRestrictedStockMember\nus-gaap:CommonStockMember\n\n2025-10-01\n2026-03-31\n\n0001506251\n\nctxr:PrefundedWarrantsMember\nus-gaap:CommonStockMember\n\n2024-10-01\n2025-03-31\n\n0001506251\n\nctxr:PrefundedWarrantsMember\nctxr:CitiusPharmaMember\nus-gaap:CommonStockMember\n\n2024-10-01\n2025-03-31\n\n0001506251\n\nctxr:PrefundedWarrantsMember\nctxr:CitiusOncologyMember\nus-gaap:CommonStockMember\n\n2024-10-01\n2025-03-31\n\n0001506251\n\nctxr:PrefundedWarrantsMember\nus-gaap:CommonStockMember\n\n2025-03-31\n\n0001506251\n\nctxr:CitiusPharmaceuticalsWarrantsMember\n\n2026-03-31\n\n0001506251\n\nus-gaap:WarrantMember\n\n2026-03-31\n\n0001506251\n\nctxr:CitiusPharmaceuticalsWarrantsMember\nus-gaap:StockOptionMember\nctxr:CitiusOncologyPlanMember\nus-gaap:CommonStockMember\n\n2026-03-31\n\n0001506251\n\nus-gaap:StockOptionMember\n\n2025-09-29\n\n0001506251\n\nus-gaap:StockOptionMember\n\n2025-09-30\n2025-09-30\n\n0001506251\n\nus-gaap:StockOptionMember\n\n2025-10-01\n2026-03-31\n\n0001506251\n\nus-gaap:StockOptionMember\n\n2025-09-30\n\n0001506251\n\nus-gaap:StockOptionMember\n\n2024-10-01\n2025-09-30\n\n0001506251\n\nus-gaap:StockOptionMember\nctxr:CitiusOncologyMember\n\n2024-09-30\n\n0001506251\n\nus-gaap:StockOptionMember\nctxr:CitiusOncologyMember\n\n2024-10-01\n2025-09-30\n\n0001506251\n\nus-gaap:StockOptionMember\nctxr:CitiusOncologyMember\n\n2025-10-01\n2026-03-31\n\n0001506251\n\nus-gaap:StockOptionMember\nctxr:CitiusOncologyMember\n\n2026-03-31\n\n0001506251\n\nus-gaap:StockOptionMember\nctxr:CitiusOncologyMember\n\n2025-09-30\n\n0001506251\n\nctxr:August2018OfferingInvestorsMember\n\n2026-03-31\n\n0001506251\n\nctxr:August2018OfferingAgentMember\n\n2026-03-31\n\n0001506251\n\nctxr:September2019OfferingInvestorsMember\n\n2026-03-31\n\n0001506251\n\nctxr:September2019OfferingUnderwriterMember\n\n2026-03-31\n\n0001506251\n\nctxr:January2021OfferingInvestorsMember\n\n2026-03-31\n\n0001506251\n\nctxr:January2021OfferingAgentMember\n\n2026-03-31\n\n0001506251\n\nctxr:May2023OfferingInvestorsMember\n\n2026-03-31\n\n0001506251\n\nctxr:May2023OfferingAgentMember\n\n2026-03-31\n\n0001506251\n\nctxr:April2024OfferingInvestorsMember\n\n2026-03-31\n\n0001506251\n\nctxr:April2024OfferingAgentMember\n\n2026-03-31\n\n0001506251\n\nctxr:November2024OfferingInvestorsMember\n\n2026-03-31\n\n0001506251\n\nctxr:November2024OfferingAgentMember\n\n2026-03-31\n\n0001506251\n\nctxr:January2025OfferingInvestorsMember\n\n2026-03-31\n\n0001506251\n\nctxr:January2025OfferingAgentMember\n\n2026-03-31\n\n0001506251\n\nctxr:April2025OfferingAgentMember\n\n2026-03-31\n\n0001506251\n\nctxr:June2025OfferingInvestorMember\n\n2026-03-31\n\n0001506251\n\nctxr:June2025OfferingAgentMember\n\n2026-03-31\n\n0001506251\n\nctxr:October2025OfferingInvestorMember\n\n2026-03-31\n\n0001506251\n\nctxr:October2025PlacementAgentMember\n\n2026-03-31\n\n0001506251\n\nctxr:December2025NotePayableExtensionMember\n\n2026-03-31\n\n0001506251\n\nctxr:CitiusPharmaceuticalsMember\n\n2026-03-31\n\n0001506251\n\nctxr:July2025OfferingInvestorsMember\n\n2026-03-31\n\n0001506251\n\nctxr:July2025OfferingAgentMember\n\n2026-03-31\n\n0001506251\n\nctxr:July2025PriorOfferingAgentMember\n\n2026-03-31\n\n0001506251\n\nctxr:September2025OfferingInvestorsMember\n\n2026-03-31\n\n0001506251\n\nctxr:September2025OfferingAgentMember\n\n2026-03-31\n\n0001506251\n\nctxr:September2025PriorOfferingAgentMember\n\n2026-03-31\n\n0001506251\n\nctxr:December2025OfferingInvestorsMember\n\n2026-03-31\n\n0001506251\n\nctxr:December2025OfferingInvestorsOneMember\n\n2026-03-31\n\n0001506251\n\nctxr:December2025PlacementOfferingAgentMember\n\n2026-03-31\n\n0001506251\n\nctxr:December2025PriorOfferingAgentMember\n\n2026-03-31\n\n0001506251\n\nctxr:CitiusOncologyWarrantsMember\n\n2026-03-31\n\n0001506251\n\nctxr:CitiusPharmaMember\nctxr:CommonStockReservedMember\n\n2026-03-31\n\n0001506251\n\nctxr:CitiusOncologyMember\nctxr:CommonStockReservedMember\n\n2026-03-31\n\n0001506251\n\n2019-07-01\n\n0001506251\n\nctxr:CitiusOncologyMember\n\n2025-10-01\n2025-12-31\n\n0001506251\n\nctxr:SupplyAgreementsMember\n\n2026-03-31\n\n0001506251\n\nsrt:MinimumMember\nus-gaap:CommonStockMember\n\n2026-02-09\n\n0001506251\n\n2026-02-09\n2026-02-09\n\n0001506251\n\nus-gaap:CommonStockMember\nus-gaap:SubsequentEventMember\n\n2026-04-22\n\n0001506251\n\nus-gaap:CommonStockMember\nus-gaap:SubsequentEventMember\n\n2026-04-24\n\n0001506251\n\nctxr:CitiusOncologyMember\nus-gaap:SubsequentEventMember\n\n2026-05-05\n\n0001506251\n\nctxr:UnderlyingWarrantMember\n\n2025-07-16\n\n0001506251\n\nctxr:UnderlyingWarrantMember\nctxr:CitiusOncologyMember\n\n2025-09-10\n\n0001506251\n\nctxr:UnderlyingWarrantMember\nctxr:CitiusOncologyMember\n\n2025-12-10\n\n0001506251\n\nctxr:UnderlyingWarrantMember\nctxr:CitiusOncologyMember\n\n2026-05-05\n\n0001506251\n\nctxr:CitiusOncologyMember\n\n2025-12-10\n\n0001506251\n\nctxr:CitiusOncologyMember\n\n2026-04-24\n\n0001506251\n\nctxr:CitiusOncologyMember\n\n2026-04-24\n2026-04-24\n\n0001506251\n\nctxr:CitiusOncologyMember\nus-gaap:SubsequentEventMember\nctxr:LoanAgreementMember\n\n2026-05-05\n\n0001506251\n\nctxr:CitiusOncologyMember\nus-gaap:SubsequentEventMember\nctxr:LoanAgreementMember\n\n2026-05-05\n2026-05-05\n\n0001506251\n\nus-gaap:SubsequentEventMember\nctxr:LoanAgreementMember\n\n2026-05-05\n2026-05-05\n\n0001506251\n\nctxr:LoanAgreementMember\n\n2025-10-01\n2026-03-31\n\n0001506251\n\nctxr:LoanAgreementMember\n\n2026-03-31\n\n0001506251\n\nctxr:LenderWarrantMember\nctxr:LoanAgreementMember\n\n2026-03-31\n\n0001506251\n\nctxr:LenderWarrantMember\nctxr:TrancheTwoMember\nctxr:LoanAgreementMember\n\n2026-03-31\n\n0001506251\n\nctxr:LenderWarrantMember\nctxr:TrancheThreeMember\nctxr:LoanAgreementMember\n\n2026-03-31\n\n0001506251\n\nctxr:LenderWarrantMember\n\n2026-03-31\n\n0001506251\n\nctxr:PromissoryNoteMember\nus-gaap:SubsequentEventMember\n\n2026-05-04\n\n0001506251\n\nctxr:PromissoryNoteMember\nus-gaap:SubsequentEventMember\n\n2026-05-04\n2026-05-04\n\nxbrli:shares\n\niso4217:USD\n\niso4217:USD\n\nxbrli:shares\n\nxbrli:pure"}